Affinium Pharmaceuticals

Skip to content

Main Navigation:

TARGETED ANTIBIOTICS FOR SERIOUS INFECTIONS

Affinium is a specialty pharmaceutical company developing a novel class of antibiotics that target the bacterial fatty acid synthesis pathway. AFN-1252, our lead clinical compound, is a highly-potent, small molecule antibiotic for both oral and IV treatment of staphylococcal infections, including MRSA and all other drug-resistant strains.

APRIL 9, 2010

Affinium Pharmaceuticals, Ltd. Announces the Initiation of a Phase I Clinical Trial Using an Optimized Oral Formulation of AFN-1252 Click for PDF version (PDF 23KB)

DECEMBER 8, 2008

Affinium Pharmaceuticals, Ltd. Announces the Initiation of a Phase I Clinical Trial for the New Tablet Form of AFN-1252, its Novel Anti-staphylococcal Antibiotic Click for PDF version (PDF 18KB)

MARCH 4, 2008

Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic Click for PDF version (PDF 18KB)

APRIL 2, 2007

Affinium Pharmaceuticals Welcomes Dr. Barry Hafkin as Chief Medical Officer Click for PDF version (PDF 18KB)

Tab1
Tab2
Tab3
Tab4

You can meet us at:

50th ICAAC, September 12-15, 2010, Boston
7th Anti-Infectives Partnering & Deal-Making Summit, October 7-8, 2010, Boston, MA
48th IDSA, October 21-24, 2010, Vancouver, Canada
BIO-Europe 2010, November 15-17, 2010, Munich, Germany